63 related articles for article (PubMed ID: 2170287)
1. Reduction of complement activation in rheumatoid arthritis by steroid treatment.
Ernst E; Espersen GT; Andersen MV
Int J Tissue React; 1990; 12(2):77-9. PubMed ID: 2170287
[TBL] [Abstract][Full Text] [Related]
2. Steroids reduce complement activation in rheumatoid arthritis.
Brandslund I; Peters ND; Ejstrup L
Int J Tissue React; 1985; 7(2):161-5. PubMed ID: 3875589
[TBL] [Abstract][Full Text] [Related]
3. Activation of classical pathway complement in chronic inflammation. Elevated levels of circulating C3d and C4d split products in rheumatoid arthritis and Crohn's disease.
Petersen NE; Elmgreen J; Teisner B; Svehag SE
Acta Med Scand; 1988; 223(6):557-60. PubMed ID: 3389208
[TBL] [Abstract][Full Text] [Related]
4. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein.
Molenaar ET; Voskuyl AE; Familian A; van Mierlo GJ; Dijkmans BA; Hack CE
Arthritis Rheum; 2001 May; 44(5):997-1002. PubMed ID: 11352263
[TBL] [Abstract][Full Text] [Related]
5. The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.
Bourke BE; Moss IK; Mumford P; Horsfall A; Maini RN
Clin Exp Immunol; 1982 Jun; 48(3):726-32. PubMed ID: 6981475
[TBL] [Abstract][Full Text] [Related]
6. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis.
Hepburn AL; Mason JC; Davies KA
Rheumatology (Oxford); 2004 May; 43(5):547-54. PubMed ID: 14747618
[TBL] [Abstract][Full Text] [Related]
7. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
Familian A; Voskuyl AE; van Mierlo GJ; Heijst HA; Twisk JW; Dijkmans BA; Hack CE
Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
[TBL] [Abstract][Full Text] [Related]
8. Complement C3c and C3d in plasma and synovial fluid in rheumatoid arthritis.
Berkowicz A; Kappelgaard E; Petersen J; Nielsen H; Ingemann-Hansen T; Halkjaer-Kristensen J; Sørensen H
Acta Pathol Microbiol Immunol Scand C; 1983 Dec; 91(6):397-402. PubMed ID: 6608857
[TBL] [Abstract][Full Text] [Related]
9. Changes in PMN leukocyte migration activity and complement C3d levels in RA patients with high disease activity during steroid treatment.
Espersen GT; Ernst E; Vestergaard M; Pedersen JO; Grunnet N
Scand J Rheumatol; 1989; 18(1):51-6. PubMed ID: 2784866
[TBL] [Abstract][Full Text] [Related]
10. Alternative pathway complement activation in rheumatoid arthritis.
El-Ghobarey A; Whaley K
J Rheumatol; 1980; 7(4):453-60. PubMed ID: 6158571
[TBL] [Abstract][Full Text] [Related]
11. Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity.
Mallya RK; Vergani D; Tee DE; Bevis L; de Beer FC; Berry H; Hamilton ED; Mace BE; Pepys MB
Clin Exp Immunol; 1982 Jun; 48(3):747-53. PubMed ID: 6981476
[TBL] [Abstract][Full Text] [Related]
12. [Complement fragment C 3d in the plasma of patients with chronic polyarthritis].
Stannat S; Peter HH; Raspe HH; Deicher H
Z Rheumatol; 1986; 45(2):47-51. PubMed ID: 3487899
[TBL] [Abstract][Full Text] [Related]
13. Steroids and complement activation in rheumatoid arthritis.
Brandslund I; Peters ND; Ejstrup L; Teisner B; Rasmussen GG
Lancet; 1983 Aug; 2(8345):346-7. PubMed ID: 6135865
[No Abstract] [Full Text] [Related]
14. [Serum complement levels in patients with rheumatoid arthritis and vasculitis].
Tomooka K
Fukuoka Igaku Zasshi; 1989 Oct; 80(10):456-66. PubMed ID: 2613159
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products.
Wouters D; Voskuyl AE; Molenaar ET; Dijkmans BA; Hack CE
Arthritis Rheum; 2006 Apr; 54(4):1143-50. PubMed ID: 16572449
[TBL] [Abstract][Full Text] [Related]
16. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation.
Wouters D; Wiessenberg HD; Hart M; Bruins P; Voskuyl A; Daha MR; Hack CE
J Immunol Methods; 2005 Mar; 298(1-2):35-45. PubMed ID: 15847795
[TBL] [Abstract][Full Text] [Related]
17. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls.
Laurberg TB; Frystyk J; Ellingsen T; Hansen IT; Jørgensen A; Tarp U; Hetland ML; Hørslev-Petersen K; Hornung N; Poulsen JH; Flyvbjerg A; Stengaard-Pedersen K
J Rheumatol; 2009 Sep; 36(9):1885-91. PubMed ID: 19684150
[TBL] [Abstract][Full Text] [Related]
18. Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density.
Tengstrand B; Larsson E; Klareskog L; Hafström I
Scand J Rheumatol; 2007; 36(5):351-8. PubMed ID: 17963164
[TBL] [Abstract][Full Text] [Related]
19. The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis.
Kirwan JR; Hickey SH; Hällgren R; Mielants H; Björck E; Persson T; Wollheim FA
Arthritis Rheum; 2006 May; 54(5):1415-21. PubMed ID: 16645969
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of an inhibitor of complement-mediated prevention of immune precipitation.
Ahmed AE; Veitch J; Whaley K
Immunology; 1990 Jun; 70(2):139-44. PubMed ID: 2373514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]